Lazard Asset Management LLC trimmed its stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 3.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 46,800 shares of the biotechnology company’s stock after selling 1,600 shares during the period. Lazard Asset Management LLC owned about 0.18% of Aclaris Therapeutics worth $1,269,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Rosenblum Silverman Sutton S F Inc. CA grew its position in Aclaris Therapeutics by 17.3% in the second quarter. Rosenblum Silverman Sutton S F Inc. CA now owns 38,400 shares of the biotechnology company’s stock valued at $1,041,000 after acquiring an additional 5,650 shares during the period. Franklin Resources Inc. grew its position in Aclaris Therapeutics by 55.4% in the second quarter. Franklin Resources Inc. now owns 1,955,381 shares of the biotechnology company’s stock valued at $53,030,000 after acquiring an additional 697,104 shares during the period. American International Group Inc. grew its position in Aclaris Therapeutics by 31.3% in the first quarter. American International Group Inc. now owns 6,804 shares of the biotechnology company’s stock valued at $203,000 after acquiring an additional 1,623 shares during the period. Schwab Charles Investment Management Inc. grew its position in Aclaris Therapeutics by 6.6% in the first quarter. Schwab Charles Investment Management Inc. now owns 43,961 shares of the biotechnology company’s stock valued at $1,311,000 after acquiring an additional 2,736 shares during the period. Finally, EcoR1 Capital LLC grew its position in Aclaris Therapeutics by 62.6% in the first quarter. EcoR1 Capital LLC now owns 673,100 shares of the biotechnology company’s stock valued at $20,072,000 after acquiring an additional 259,100 shares during the period. Hedge funds and other institutional investors own 95.79% of the company’s stock.

A number of analysts have weighed in on ACRS shares. Jefferies Group LLC reiterated a “buy” rating and issued a $36.00 price target on shares of Aclaris Therapeutics in a research report on Monday, July 31st. BidaskClub raised Aclaris Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, July 24th. Guggenheim reissued a “buy” rating and issued a $40.00 price objective on shares of Aclaris Therapeutics in a research note on Tuesday, July 4th. Cantor Fitzgerald set a $50.00 price objective on Aclaris Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Finally, ValuEngine raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, June 15th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $40.00.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) opened at 26.05 on Thursday. The firm’s market cap is $696.47 million. The firm has a 50-day moving average price of $25.99 and a 200-day moving average price of $27.57. Aclaris Therapeutics, Inc. has a 1-year low of $20.15 and a 1-year high of $33.25.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.56) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.12. On average, analysts expect that Aclaris Therapeutics, Inc. will post ($3.10) earnings per share for the current fiscal year.

In other Aclaris Therapeutics news, Director Andrew N. Schiff purchased 108,601 shares of the firm’s stock in a transaction dated Wednesday, August 16th. The shares were bought at an average price of $23.02 per share, for a total transaction of $2,499,995.02. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 16.30% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Lazard Asset Management LLC Has $1.27 Million Holdings in Aclaris Therapeutics, Inc. (ACRS)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.thecerbatgem.com/2017/09/28/lazard-asset-management-llc-has-1-27-million-holdings-in-aclaris-therapeutics-inc-acrs.html.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aclaris Therapeutics, Inc. (NASDAQ:ACRS).

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Stock Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related stocks with our FREE daily email newsletter.